Table 1.
Parameters | All (n = 166) | Non-Survivor (n = 45) | Survivor (n = 121) | P |
---|---|---|---|---|
Demographic Data | ||||
Age, mean (SD),y | 47.49 (15.06) | 49.67 (13.73) | 46.68 (15.53) | 0.310 |
Male, n (%) | 97 (58.43) | 25 (55.60) | 72 (59.50) | 0.646 |
Etiology, n (%) | 0.007 | |||
Biliary | 71 (42.80) | 15 (33.30) | 56 (46.30) | |
Hyperlipidemia | 34 (20.50) | 5 (11.10) | 29 (24.00) | |
Others | 61 (36.70) | 25 (55.60) | 36 (29.80) | |
Underlying medical conditions | ||||
Hypertension, n (%) | 24 (14.50) | 5 (11.10) | 19 (15.70) | 0.455 |
Diabetes Mellitus, n (%) | 28 (16.90) | 5 (11.10) | 23 (19.00) | 0.227 |
Severity, n (%) | 0.533 | |||
Moderately severe | 27 (16.30) | 6 (13.30) | 21 (17.40) | |
Severe | 139 (83.70) | 39 (86.70) | 100 (82.60) | |
APACHEIIScorea, mean (SD) | 19.27 (7.32) | 22.53 (5.69) | 18.03 (7.50) | < 0.001 |
Ranson’s Scorea, mean (SD) | 4.24 (1.55) | 4.29 (1.61) | 4.11 (1.36) | 0.493 |
CHOLa, mean (SD), mmol/L | 3.41 (2.79) | 3.00 (3.42) | 3.00 (3.42) | 0.257 |
HDL-Ca, mean (SD), mmol/L | 0.39 (0.28) | 0.26 (0.13) | 0.44 (0.31) | < 0.001 |
LDL-Ca, mean (SD), mmol/L | 0.91 (0.70) | 0.54 (0.53) | 1.05 (0.71) | < 0.001 |
H/L ratioa, mean (SD) | 0.72 (0.92) | 0.93 (1.29) | 0.64 (0.72) | < 0.001 |
Statins usage**, n (%) | 2 (1.20) | 1 (2.22) | 1 (0.82) | 0.464 |
Ventilation free daysb, mean (SD), d | 16.87 (8.93) | 13.64 (9.16) | 18.07 (8.56) | 0.004 |
Renal replacement therapy, n (%) | 27 (16.30) | 12 (26.70) | 15 (12.40) | 0.149 |
Hospital cost, mean (SD), CHY | 182,392.76 (141,028) | 229,767 (163.568) | 164,627 (127,869) | 0.008 |
ICU LOS, mean (SD), d | 23.37 (22.40) | 20.91 (16.56) | 24.28 (24.22) | 0.391 |
Hospital LOS, mean (SD), d | 30.54 (23.30) | 23.27 (17.18) | 33.27 (24.73) | 0.014 |
APACHE Acute Physiology and Chronic Health Evaluation, CHOL cholesterol, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, H/L HDL-C/ LDL-C, LOS length of stay
aon admission
bwithin 28 days